A Second Opinion on Pharmaceutical Reverse Payment Settlements: Why Actavis Missed the Mark

This document cites

• US Code - 21 U.S.C. § 355-1 Risk Evaluation and Mitigation Strategies
• Federal Cases - Toyota Motor Manufacturing v Williams
• Federal Cases - Federal Trade Commission v. Indiana Federation of Dentists
• Federal Cases - IN RE ANDROGEL ANTITRUST LITIGATION (NO. II)
• Federal Cases - Northern Pacific Railway Company v. United States



See all quotations

• Federal Cases - In re Tamoxifen Citrate Antitrust Litigation
• Federal Cases - F.T.C. v. Cephalon, Inc.
• Federal Cases - National Collegiate Athletic Association v. Board of Regents of University of Oklahoma
• Federal Cases - Sutton v United Air Lines
• Federal Cases - Transource Intern., Inc. v. Trinity Industries, Inc.
• Federal Cases - Schering-Plough Corp. v. F.T.C.
• Federal Cases - Board of Trade of City of Chicago v. United States
• Federal Cases - In re Ciprofloxacin Hydrochloride Antitrust Lit.
• Federal Cases - In re K–Dur Antitrust Litig.
• Federal Cases - In re Terazosin Hydrochloride Antitrust Litigation
• Federal Cases - Fed. Trade Comm'n v. Watson Pharms., Inc.
• Federal Cases - Valley Drug Co. v. Geneva Pharm., Inc.
• Federal Cases - Continental Inc v. Gte Sylvania Incorporated
• Federal Cases - Andrx Pharmaceuticals, Inc. v. Elan Corp., Plc
• Federal Cases - Ark. Carpenters Health And Welfare Fund v. Bayer Ag
• Federal Cases - Fed. Trade Comm'n v. Watson Pharm., Inc.